DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC)

DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With Topotecan

IDENTIFIER (ClinicalTrials.gov): NCT05990738

DRUG/TREATMENT: BI 764532 (DLL3/CD3 bispecific antibody) + Topotecan

PHASE: 1

STATUS: Recruiting

SPONSOR: Boehringer Ingelheim

DESCRIPTION:

Dr. Aman Chauhan at Sylvester Comprehensive Cancer Center, University of Miami discusses the DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC). Recorded: June 20, 2024

Boehringer Ingelheim is sponsoring a phase 1 study, a phase 1 trial studying  BI 764532, an antibody-like molecule (DLL3/CD3 bispecific or “BiTE”) that may help the immune system fight cancer. 

The study is in adults with extensive stage small cell lung cancer who have previously received platinum-based chemotherapy and are eligible to receive topotecan treatment.

The purpose of this study is to find out the highest dose of BI 764532 that people can tolerate when taken together with topotecan, a chemotherapy treatment called topoisomerase 1 inhibitor, that works by blocking a chemical (topoisomerase 1) that helps cancer cells repair and separate DNA when they divide. Participants get BI 764532 and topotecan as infusions into a vein. As an alternative, topotecan may also be taken orally (tablets).

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

CONTACT:

Boehringer Ingelheim

EMAIL: clintriage.rdg@boehringer-ingelheim.com

PHONE: 1-800-243-0127